In today’s episode of the Psychedelic Spotlight podcast, we sit down with Doug Drysdale, CEO of Cybin, a biotechnology company focused on creating new, effective, and accessible psychedelic-based therapies.
In our conversation, Doug talks about the company’s mission to revolutionize mental healthcare, how Cybin is delivering powerful and effective therapies, and why being the first psychedelic-based company to list on the New York Stock Exchange was a natural fit. Cybin can be found on the NYSE under the ticker symbol $CYBN.
*To learn more about Cybin and the work they’re doing, visit their website: Cybin.com
*Subscribe to our newsletter to get the latest industry news: PsychedelicSpotlight.com
Instagram: @PsycSpotlight
Twitter: @PsycSpotlight
Facebook: PsychedelicSpotlight
YouTube: PsychedelicSpotlight
LinkedIn: Psychedelic-Spotlight
*This interview was recorded on September 2, 2021.
